IRX Therapeutics Receives $2,000,000 New Financing

  • Feed Type
  • Date
    5/13/2016
  • Company Name
    IRX Therapeutics
  • Mailing Address
    140 West 57th Street New York, NY 10019 USA
  • Company Description
    IRX Therapeutics’ mission is to discover and commercialize drugs that stimulate a coordinated TH1-specific cellular immune response to treat human diseases. This immune response is essential for the eradication of most viruses and tumors, and relies on the effective functioning of dendritic cells, macrophages, and T-cells.
  • Website
    http://www.irxtherapeutics.com
  • Transaction Type
    Debt
  • Transaction Amount
    $2,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. 1 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed